肝移植治疗肝内胆管癌的研究进展

汪国营; 何才华

doi:10.3969/j.issn.1674-7445.2023144

肝移植治疗肝内胆管癌的研究进展

doi: 10.3969/j.issn.1674-7445.2023144

汪国营^,,
何才华

510120　广州，广州医科大学附属第一医院肝胆外科

基金项目: 广东省自然科学基金面上项目（2022A1515010519）；广州市基础研究计划市校（院）联合资助项目（202201020439）；广州市临床特色技术项目（2023C-TS18）

详细信息

通讯作者:
汪国营（ORCID: 0000-0002-0304-0986），Email：wanggy3@126.com

中图分类号: R617， R735.7
计量
- 文章访问数: 336
- HTML全文浏览量: 325
- PDF下载量: 46
- 被引次数: 0
出版历程
- 收稿日期: 2023-07-22
- 网络出版日期: 2023-08-25
- 刊出日期: 2023-11-09

Progress in liver transplantation for intrahepatic cholangiocarcinoma

Wang Guoying^,,
He Caihua

Department of Hepatobiliary Surgery, the First Affiliated Hospital of Guangzhou Medical University, Guangzhou 510120, China

More Information

Corresponding author: Wang Guoying, Email: wanggy3@126.com

摘要

摘要: 肝内胆管癌（ICC）是仅次于肝细胞癌的肝脏原发性恶性肿瘤，其发病率在全球范围内呈上升趋势。肝切除术一直是ICC患者外科治疗的首选，而ICC过去由于高肿瘤复发率和较差的生存结果，被视为肝移植禁忌证。目前，ICC肝移植治疗已经取得了诸多重要进展，对于严格筛选的ICC患者，肝移植或在新辅助治疗后肝移植取得了令人鼓舞的生存结果。同时，随着ICC肝移植治疗预后风险分层的完善，也将进一步优化ICC肝移植候选者的选择标准。此外，ICC现代多模式综合治疗的发展，也将进一步指导ICC肝移植术前新辅助治疗方案的选择。ICC肝移植前应用免疫检查点抑制剂也是未来重要的研究方向。本文从ICC肝移植治疗的预后、ICC肝移植的预后风险因素及候选者选择标准、正在进行的试验和挑战进行总结，以期为肝移植治疗ICC提供参考，提高ICC患者的生存质量。
- 肝内胆管癌 /
- 肝移植 /
- 肝细胞癌 /
- 肝切除 /
- 新辅助治疗 /
- 复发 /
- 化学药物治疗 /
- 免疫治疗 /
- 免疫检查点抑制剂
Abstract: Intrahepatic cholangiocarcinoma (ICC) is a primary malignant tumor of the liver, secondary to hepatocellular carcinoma, and its incidence tends to elevate worldwide. Hepatectomy is the optimal surgical regimen for ICC patients. ICC is considered as a contraindication for liver transplantation due to high tumor recurrence rate and poor survival outcome. At present, multiple significant progresses have been made in liver transplantation for ICC. For strictly-selected ICC patients, liver transplantation or liver transplantation after neoadjuvant therapy has achieved encouraging survival outcomes. Meantime, with the improvement of prognostic risk stratification of liver transplantation for ICC, the inclusion criteria of ICC candidates undergoing liver transplantation will be further optimized. In addition, the advancement of modern multi-mode comprehensive treatment of ICC will further guide the selection of neoadjuvant therapy before liver transplantation for ICC. The application of immune checkpoint inhibitors in ICC before liver transplantation is also an important research direction in the future. In this article, clinical prognosis of liver transplantation for ICC, prognostic risk factors and inclusion criteria of ICC candidates undergoing liver transplantation, and the ongoing trials and existing challenges were summarized, aiming to provide reference for liver transplantation for ICC and improve the quality of life for ICC patients.
- Intrahepatic cholangiocarcinoma /
- Liver transplantation /
- Hepatocellular carcinoma /
- Hepatectomy /
- Neoadjuvant therapy /
- Recurrence /
- Chemotherapy /
- Immunotherapy /
- Immune checkpoint inhibitor

HTML全文

下载: 全尺寸图片幻灯片

参考文献(43)

[1]	SUNG H, FERLAY J, SIEGEL RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]	AN L, ZHENG R, ZHANG S, et al. Hepatocellular carcinoma and intrahepatic cholangiocarcinoma incidence between 2006 and 2015 in China: estimates based on data from 188 population-based cancer registries[J]. Hepatobiliary Surg Nutr, 2023, 12(1): 45-55. DOI: 10.21037/hbsn-21-75.
[3]	中国抗癌协会肝癌专业委员会胆管癌协作组. 原发性肝癌诊疗指南之肝内胆管癌诊疗中国专家共识(2022版)[J]. 中华消化外科杂志, 2022, 21(10): 1269-1301. DOI: 10.3760/cma.j.cn115610-20220829-00476. Biliary Cancer Collaborative Group of the Liver Cancer Professional Committee of the China Anti Cancer Association. Chinese expert consensus on management of intrahepatic cholangiocarcinoma (2022 edition)[J]. Chin J Dig Surg, 2022, 21(10): 1269-1301. DOI: 10.3760/cma.j.cn115610-20220829-00476.
[4]	MAZZAFERRO V, GORGEN A, ROAYAIE S, et al. Liver resection and transplantation for intrahepatic cholangiocarcinoma[J]. J Hepatol, 2020, 72(2): 364-377. DOI: 10.1016/j.jhep.2019.11.020.
[5]	SAPISOCHIN G, IVANICS T, HEIMBACH J. Liver transplantation for intrahepatic cholangiocarcinoma: ready for prime time? [J]. Hepatology, 2022, 75(2): 455-472. DOI: 10.1002/hep.32258.
[6]	KODALI S, SAHARIA A, GHOBRIAL RM. Liver transplantation and intrahepatic cholangiocarcinoma: time to go forward again? [J]. Curr Opin Organ Transplant, 2022,27(4):320-328. DOI: 10.1097/MOT.0000000000000983.
[7]	ZIOGAS IA, GIANNIS D, ECONOMOPOULOS KP, et al. Liver transplantation for intrahepatic cholangiocarcinoma: a meta-analysis and meta-regression of survival rates[J]. Transplantation, 2021, 105(10): 2263-2271. DOI: 10.1097/TP.0000000000003539.
[8]	HARA T, EGUCHI S, YOSHIZUMI T, et al. Incidental intrahepatic cholangiocarcinoma in patients undergoing liver transplantation: a multi-center study in Japan[J]. J Hepatobiliary Pancreat Sci, 2021, 28(4): 346-352. DOI: 10.1002/jhbp.896.
[9]	TAKAHASHI K, OBEID J, BURMEISTER CS, et al. Intrahepatic cholangiocarcinoma in the liver explant after liver transplantation: histological differentiation and prognosis[J]. Ann Transplant, 2016, 21: 208-215. DOI: 10.12659/aot.895936.
[10]	DE MARTIN E, RAYAR M, GOLSE N, et al. Analysis of liver resection versus liver transplantation on outcome of small intrahepatic cholangiocarcinoma and combined hepatocellular-cholangiocarcinoma in the setting of cirrhosis[J]. Liver Transpl, 2020, 26(6): 785-798. DOI: 10.1002/lt.25737.
[11]	HUE JJ, ROCHA FG, AMMORI JB, et al. A comparison of surgical resection and liver transplantation in the treatment of intrahepatic cholangiocarcinoma in the era of modern chemotherapy: an analysis of the National Cancer Database[J]. J Surg Oncol, 2021, 123(4): 949-956. DOI: 10.1002/jso.26370.
[12]	KIM P, LITTAU M, BAKER TB, et al. Intrahepatic cholangiocarcinoma: is there a role for liver transplantation? [J]. Surgery, 2022, 171(3): 741-746. DOI: 10.1016/j.surg.2021.09.034.
[13]	HUANG G, SONG W, ZHANG Y, et al. Liver transplantation for intrahepatic cholangiocarcinoma: a propensity score-matched analysis[J]. Sci Rep, 2023, 13(1): 10630. DOI: 10.1038/s41598-023-37896-2.
[14]	SAPISOCHIN G, RODRÍGUEZ DE LOPE C, GASTACA M, et al. "Very early" intrahepatic cholangiocarcinoma in cirrhotic patients: should liver transplantation be reconsidered in these patients? [J]. Am J Transplant, 2014, 14(3): 660-667. DOI: 10.1111/ajt.12591.
[15]	SAPISOCHIN G, FACCIUTO M, RUBBIA-BRANDT L, et al. Liver transplantation for "very early" intrahepatic cholangiocarcinoma: international retrospective study supporting a prospective assessment[J]. Hepatology, 2016, 64(4): 1178-1188. DOI: 10.1002/hep.28744.
[16]	GUPTA R, TOGASHI J, AKAMATSU N, et al. Impact of incidental/misdiagnosed intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma on the outcomes of liver transplantation: an institutional case series and literature review[J]. Surg Today, 2017, 47(8): 908-917. DOI: 10.1007/s00595-017-1472-3.
[17]	JUNG DH, HWANG S, SONG GW, et al. Clinicopathological features and prognosis of intrahepatic cholangiocarcinoma after liver transplantation and resection[J]. Ann Transplant, 2017, 22: 42-52. DOI: 10.12659/aot.901504.
[18]	SAPISOCHIN G, DE LOPE CR, GASTACA M, et al. Intrahepatic cholangiocarcinoma or mixed hepatocellular-cholangiocarcinoma in patients undergoing liver transplantation: a Spanish matched cohort multicenter study[J]. Ann Surg, 2014, 259(5): 944-952. DOI: 10.1097/SLA.0000000000000494.
[19]	LEE DD, CROOME KP, MUSTO KR, et al. Liver transplantation for intrahepatic cholangiocarcinoma[J]. Liver Transpl, 2018, 24(5): 634-644. DOI: 10.1002/lt.25052.
[20]	吴凤东, 史斌. 肝内胆管癌肝移植及其综合治疗[J]. 器官移植, 2021, 12(3): 344-350. DOI: 10.3969/j.issn.1674-7445.2021.03.014. WU FD, SHI B. Liver transplantation and comprehensive treatment of intrahepatic cholangiocarcinoma[J]. Organ Transplant, 2021, 12(3): 344-350. DOI: 10.3969/j.issn.1674-7445.2021.03.014.
[21]	HONG JC, JONES CM, DUFFY JP, et al. Comparative analysis of resection and liver transplantation for intrahepatic and hilar cholangiocarcinoma: a 24-year experience in a single center[J]. Arch Surg, 2011, 146(6): 683-689. DOI: 10.1001/archsurg.2011.116.
[22]	LUNSFORD KE, JAVLE M, HEYNE K, et al. Liver transplantation for locally advanced intrahepatic cholangiocarcinoma treated with neoadjuvant therapy: a prospective case-series[J]. Lancet Gastroenterol Hepatol, 2018, 3(5): 337-348. DOI: 10.1016/S2468-1253(18)30045-1.
[23]	ABDELRAHIM M, AL-RAWI H, ESMAIL A, et al. Gemcitabine and cisplatin as neo-adjuvant for cholangiocarcinoma patients prior to liver transplantation: case-series[J]. Curr Oncol, 2022, 29(5): 3585-3594. DOI: 10.3390/curroncol29050290.
[24]	ABDELRAHIM M, ESMAIL A, XU J, et al. Gemcitabine plus cisplatin versus non-gemcitabine and cisplatin regimens as neoadjuvant treatment for cholangiocarcinoma patients prior to liver transplantation: an institution experience[J]. Front Oncol, 2022, 12: 908687. DOI: 10.3389/fonc.2022.908687.
[25]	RAYAR M, LEVI SANDRI GB, HOUSSEL-DEBRY P, et al. Multimodal therapy including Yttrium-90 radioembolization as a bridging therapy to liver transplantation for a huge and locally advanced intrahepatic cholangiocarcinoma[J]. J Gastrointestin Liver Dis, 2016, 25(3): 401-404. DOI: 10.15403/jgld.2014.1121.253.y90.
[26]	MCMILLAN RR, JAVLE M, KODALI S, et al. Survival following liver transplantation for locally advanced, unresectable intrahepatic cholangiocarcinoma[J]. Am J Transplant, 2022, 22(3): 823-832. DOI: 10.1111/ajt.16906.
[27]	ITO T, BUTLER JR, NOGUCHI D, et al. A 3-decade, single-center experience of liver transplantation for cholangiocarcinoma: impact of era, tumor size, location, and neoadjuvant therapy[J]. Liver Transpl, 2022, 28(3): 386-396. DOI: 10.1002/lt.26285.
[28]	孙大伟,蒋文涛,钟林,等. 肝移植治疗肝内胆管细胞癌临床疗效的多中心研究[J]. 中华消化外科杂志, 2023,22(2):230-235. DOI: 10.3760/cma.j.cn115610- 20221219-00753. SUN DW, JIANG WT, ZHONG L, et al. Clinical efficacy of liver transplantation for intrahepatic cholangiocarcinoma: a multicenter study[J]. Chin J Dig Surg, 2023,22(2):230-235. DOI: 10.3760/cma.j.cn115610-20221219-00753.
[29]	KODALI S, CONNOR AA, THABET S, et al. Comparison of resection versus liver transplantation for intrahepatic cholangiocarcinoma: past, present, and future directions[J]. Hepatobiliary Pancreat Dis Int, 2023, DOI: 10.1016/j.hbpd.2023.07.007[Epub ahead of print
[30]	吕国悦, 孙大伟. 肝内胆管细胞癌肝移植治疗的预后分析与策略选择[J]. 中华消化外科杂志, 2023, 22(2): 187-194. DOI: 10.3760/cma.j.cn115610-20221123-00707. LYU GY, SUN DW. Prognosis analysis and strategies selection in liver transplantation for intrahepatic cholangio-carcinoma[J]. Chin J Dig Surg, 2023, 22(2): 187-194. DOI: 10.3760/cma.j.cn115610-20221123-00707.
[31]	HONG JC, PETROWSKY H, KALDAS FM, et al. Predictive index for tumor recurrence after liver transplantation for locally advanced intrahepatic and hilar cholangiocarcinoma[J]. J Am Coll Surg, 2011, 212(4): 514-521. DOI: 10.1016/j.jamcollsurg.2010.12.005.
[32]	DUIGNAN S, MAGUIRE D, RAVICHAND CS, et al. Neoadjuvant chemoradiotherapy followed by liver transplantation for unresectable cholangiocarcinoma: a single-centre national experience[J]. HPB (Oxford), 2014, 16(1): 91-98. DOI: 10.1111/hpb.12082.
[33]	REN A, LI Z, CHENG P, et al. Systemic immune-inflammation index is a prognostic predictor in patients with intrahepatic cholangiocarcinoma undergoing liver transplantation[J]. Mediators Inflamm, 2021: 6656996. DOI: 10.1155/2021/6656996.
[34]	杨发才,游川,雷正清,等. 肿瘤负荷评分联合淋巴结分期对肝内胆管细胞癌患者术后生存预测价值[J/CD]. 中华肝脏外科手术学电子杂志, 2023,12(4):389-394. DOI: 10.3877/cma.j.issn.2095-3232.2023.04.006. YANG FC, YOU C, LEI ZQ, et al. Predictive value of tumor burden score combined with lymph node staging for postoperative survival of intrahepatic cholangiocarcinoma patients[J/CD]. Chin J Hepatic Surg (Electr Edit), 2023,12(4):389-394. DOI: 10.3877/cma.j.issn.2095-3232.2023.04.006.
[35]	LEI Z, MA W, SI A, et al. Effect of different PD-1 inhibitor combination therapies for unresectable intrahepatic cholangiocarcinoma[J]. Aliment Pharmacol Ther, 2023, 58(6): 611-622. DOI: 10.1111/apt.17623.
[36]	ZHU SG, LI HB, DAI TX, et al. Successful treatment of stage IIIB intrahepatic cholangiocarcinoma using neoadjuvant therapy with the PD-1 inhibitor camrelizumab: a case report[J]. World J Clin Cases, 2022, 10(27): 9743-9749. DOI: 10.12998/wjcc.v10.i27.9743.
[37]	Liver transplantation for early intrahepatic cholangiocarcinoma (LT for iCCA) [EB/OL]. [2023-07-01]. https://classic.clinicaltrials.gov/ct2/show/NCT02878473?term=NCT02878473.
[38]	Liver transplantation for stable, advanced intrahepatic cholangiocarcinoma[EB/OL]. [2023-07-01]. https://clinicaltrials. gov/study/NCT04195503?term=NCT04195503.
[39]	Liver transplantation for non-resectable intrahepatic cholangiocarcinoma: a prospective exploratory trial (TESLA Trial) [EB/OL]. [2023-07-01]. https://clinicaltrials.gov/study/NCT04556214?term=NCT04556214.
[40]	宋方彬, 李善宝, 徐军明. 肝移植治疗肝内胆管癌的现状与挑战[J]. 肝脏, 2022, 27(5): 514-515, 520. DOI: 10.3969/j.issn.1008-1704.2022.05.005. SONG FB, LI SB, XU JM. Current status and challenges of liver transplantation for intrahepatic cholangiocarcinoma[J]. Chin Hepatol, 2022, 27(5): 514-515, 520. DOI: 10.3969/j.issn.1008-1704.2022.05.005.
[41]	SAPISOCHIN G, JAVLE M, LERUT J, et al. Liver transplantation for cholangiocarcinoma and mixed hepatocellular cholangiocarcinoma: working group report from the ILTS transplant oncology consensus conference[J]. Transplantation, 2020, 104(6): 1125-1130. DOI: 10.1097/TP.0000000000003212.
[42]	BOERNER T, DRILL E, PAK LM, et al. Genetic determinants of outcome in intrahepatic cholangiocarcinoma[J]. Hepatology, 2021, 74(3): 1429-1444. DOI: 10.1002/hep.31829.
[43]	MOECKLI B, IVANICS T, CLAASEN M, et al. Recent developments and ongoing trials in transplant oncology[J]. Liver Int, 2020, 40(10): 2326-2344. DOI: 10.1111/liv.14621.